656 related articles for article (PubMed ID: 33717088)
1. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.
Renrick AN; Thounaojam MC; de Aquino MTP; Chaudhuri E; Pandhare J; Dash C; Shanker A
Front Immunol; 2021; 12():607044. PubMed ID: 33717088
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract][Full Text] [Related]
4. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity.
Huffaker TB; Hu R; Runtsch MC; Bake E; Chen X; Zhao J; Round JL; Baltimore D; O'Connell RM
Cell Rep; 2012 Dec; 2(6):1697-709. PubMed ID: 23200854
[TBL] [Abstract][Full Text] [Related]
5. Immunopharmacological effect of β-d-mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR-155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients.
Mortazavi-Jahromi SS; Aslani M; Omidian S; Ahmadzadeh A; Rezaieyazdi Z; Mirshafiey A
Drug Dev Res; 2020 May; 81(3):295-304. PubMed ID: 31675124
[TBL] [Abstract][Full Text] [Related]
6. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.
Ji Y; Wrzesinski C; Yu Z; Hu J; Gautam S; Hawk NV; Telford WG; Palmer DC; Franco Z; Sukumar M; Roychoudhuri R; Clever D; Klebanoff CA; Surh CD; Waldmann TA; Restifo NP; Gattinoni L
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):476-81. PubMed ID: 25548153
[TBL] [Abstract][Full Text] [Related]
7. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
[TBL] [Abstract][Full Text] [Related]
8. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
Huang Z; Peng S; Knoff J; Lee SY; Yang B; Wu TC; Hung CF
J Biomed Sci; 2015 Jan; 22(1):7. PubMed ID: 25591912
[TBL] [Abstract][Full Text] [Related]
9. miR-155 influences cell-mediated immunity in Balb/c mice treated with aflatoxin M
Shirani K; Riahi Zanjani B; Mehri S; Razavi-Azarkhiavi K; Badiee A; Hayes AW; Giesy JP; Karimi G
Drug Chem Toxicol; 2021 Jan; 44(1):39-46. PubMed ID: 30739504
[TBL] [Abstract][Full Text] [Related]
10. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
[TBL] [Abstract][Full Text] [Related]
11. miR-149-3p reverses CD8
Zhang M; Gao D; Shi Y; Wang Y; Joshi R; Yu Q; Liu D; Alotaibi F; Zhang Y; Wang H; Li Q; Zhang ZX; Koropatnick J; Min W
Open Biol; 2019 Oct; 9(10):190061. PubMed ID: 31594465
[TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
13. TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.
Guo J; Liao M; Wang J
Cell Commun Signal; 2021 Sep; 19(1):90. PubMed ID: 34479599
[TBL] [Abstract][Full Text] [Related]
14. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
15. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
Zimmerer JM; Lesinski GB; Kondadasula SV; Karpa VI; Lehman A; Raychaudhury A; Becknell B; Carson WE
J Immunol; 2007 Apr; 178(8):4832-45. PubMed ID: 17404264
[TBL] [Abstract][Full Text] [Related]
16. Activin-A impedes the establishment of CD4
Morianos I; Tsitsopoulou A; Potaris K; Valakos D; Fari O; Vatsellas G; Bostantzoglou C; Photiades A; Gaga M; Xanthou G; Semitekolou M
J Exp Clin Cancer Res; 2021 Sep; 40(1):295. PubMed ID: 34548096
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation.
Jiang K; Yang J; Guo S; Zhao G; Wu H; Deng G
Mol Ther; 2019 Oct; 27(10):1758-1771. PubMed ID: 31405809
[TBL] [Abstract][Full Text] [Related]
18. miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1.
Lind EF; Millar DG; Dissanayake D; Savage JC; Grimshaw NK; Kerr WG; Ohashi PS
J Immunol; 2015 Nov; 195(10):4632-40. PubMed ID: 26447227
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A; Sempere LF; Carmona SJ; Carretero-Iglesia L; Monnot G; Speiser DE; Rufer N; Donda A; Zehn D; Jandus C; Romero P
Cancer Immunol Res; 2019 Jun; 7(6):1013-1024. PubMed ID: 31043416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
